PMV Pharma reports Q3 2026 results, plans rezatapopt NDA filing in Q1 2027
PMV Pharma said completed enrollment and updated Phase 2 data support an accelerated approval filing for ovarian cancer, backed by a $50 million offering.
SEC filing
3 stories
PMV Pharma said completed enrollment and updated Phase 2 data support an accelerated approval filing for ovarian cancer, backed by a $50 million offering.
SEC filing
PMV Pharmaceuticals appointed Matt Eckler, Ph.D. as director on October 1, 2026, as the company prepares to file for accelerated approval of rezatapopt in the first quarter of 2027.
SEC filing
The company signed its underwriting agreement and set final terms for the stock and warrant offering that priced August 31, 2026, closing September 2.
SEC filing (3)